Company / Operating Cash Flow
BridgeBio Pharma, Inc. Operating Cash Flow History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$445.9M
FY2025
5-year range
-$520.7M / -$253.6M
FY2021-FY2025
Trend
+14.4%
vs FY2024
Sector context
#206 of 216
Health Care
What the data says
Among 216 Health Care companies, BridgeBio Pharma, Inc. is in the bottom 5% for operating cash flow. Operating Cash Flow returned to growth in FY2025 after 3 years of decline, reaching -$446M.
Based on SEC 10-K filings.
-$446M in FY2025.
Improved from -$498M to -$446M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 216This company -$445.9M Sector average $659.0M
▼
-167.7% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 14.4% year-over-year.
- Ranks #206 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2017.
- Lowest operating cash flow in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$445.9M | +14.4% |
| FY2024 | -$520.7M | -4.6% |
| FY2023 | -$497.9M | -18.7% |
| FY2022 | -$419.5M | -65.4% |
| FY2021 | -$253.6M | +36.6% |
| FY2020 | -$399.7M | -57.6% |
| FY2019 | -$253.6M | -85.6% |
| FY2018 | -$136.6M | -237.5% |
| FY2017 | -$40.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026